Actuate Therapeutics Receives Nasdaq Bid Price Deficiency Notice

Actuate Therapeutics, Inc. (Nasdaq: ACTU) received a written notice from The Nasdaq Stock Market LLC on Oct. 28, 2026, saying its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days, the company said in an 8-K filed Friday, Oct. 30.

The notice was issued under Nasdaq Listing Rule 5450(a)(1) and applies to continued inclusion on The Nasdaq Global Market. It has no immediate effect. The common stock continues to trade on the Nasdaq Global Market under the symbol "ACTU."

Compliance period

Under Nasdaq Listing Rule 5810(c)(3)(A), the company has an initial 180-calendar-day compliance period, through April 26, 2027. To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days within that period, and the company must otherwise meet Nasdaq Global Market requirements.

If it does not regain compliance, the company may receive a second 180-day period if it applies to transfer its listing to the Nasdaq Capital Market and notifies Nasdaq of its intent to cure the deficiency. To qualify, it must meet the market value of publicly held shares requirement and the other initial listing standards for the Capital Market, except the bid price rule. Otherwise, the stock will be subject to delisting.

Separate market value notice

The company also received a notice on July 15, 2026, for not meeting the minimum market value of listed securities requirement. It has until Jan. 11, 2027, to regain compliance with that requirement, and the bid price notice does not change that deadline.

The company said it is monitoring its closing bid price and will consider all available options. It also said there is no assurance it will regain compliance, secure a second period, or succeed in any appeal of a delisting determination.